JP2011522792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522792A5 JP2011522792A5 JP2011507897A JP2011507897A JP2011522792A5 JP 2011522792 A5 JP2011522792 A5 JP 2011522792A5 JP 2011507897 A JP2011507897 A JP 2011507897A JP 2011507897 A JP2011507897 A JP 2011507897A JP 2011522792 A5 JP2011522792 A5 JP 2011522792A5
- Authority
- JP
- Japan
- Prior art keywords
- poly
- particulate carrier
- carrier according
- agent
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 239000012867 bioactive agent Substances 0.000 claims 9
- 229920000642 polymer Polymers 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 239000008346 aqueous phase Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000012074 organic phase Substances 0.000 claims 6
- -1 poly (vinyl halide Chemical class 0.000 claims 5
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 claims 3
- 150000001450 anions Chemical class 0.000 claims 3
- 150000001768 cations Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- 239000010419 fine particle Substances 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- 229920001710 Polyorthoester Polymers 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical group [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000002745 poly(ortho ester) Substances 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 229920001651 Cyanoacrylate Polymers 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229960000800 cetrimonium bromide Drugs 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 150000001993 dienes Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 150000001261 hydroxy acids Chemical class 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DDBRXOJCLVGHLX-UHFFFAOYSA-N n,n-dimethylmethanamine;propane Chemical compound CCC.CN(C)C DDBRXOJCLVGHLX-UHFFFAOYSA-N 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- UCUUFSAXZMGPGH-UHFFFAOYSA-N penta-1,4-dien-3-one Chemical compound C=CC(=O)C=C UCUUFSAXZMGPGH-UHFFFAOYSA-N 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920002959 polymer blend Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920000098 polyolefin Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 claims 1
- 229920001567 vinyl ester resin Polymers 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5077508P | 2008-05-06 | 2008-05-06 | |
| US61/050,775 | 2008-05-06 | ||
| US7417108P | 2008-06-20 | 2008-06-20 | |
| US61/074,171 | 2008-06-20 | ||
| PCT/EP2009/055436 WO2009135853A2 (en) | 2008-05-06 | 2009-05-05 | Encapsulation of biologically active agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522792A JP2011522792A (ja) | 2011-08-04 |
| JP2011522792A5 true JP2011522792A5 (enExample) | 2012-06-07 |
Family
ID=40944671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507897A Pending JP2011522792A (ja) | 2008-05-06 | 2009-05-05 | 生物活性薬の封入 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110064821A1 (enExample) |
| EP (2) | EP2441447A1 (enExample) |
| JP (1) | JP2011522792A (enExample) |
| KR (3) | KR20110010760A (enExample) |
| AR (4) | AR071633A1 (enExample) |
| CA (1) | CA2721241A1 (enExample) |
| CL (4) | CL2009001076A1 (enExample) |
| PE (4) | PE20091829A1 (enExample) |
| TW (4) | TW201006495A (enExample) |
| UY (4) | UY31809A (enExample) |
| WO (1) | WO2009135853A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0912372A2 (pt) * | 2008-05-06 | 2017-09-26 | Glaxo Group Ltd | nanopartículas, composição, método para dispensar uma proteína através da barreira hematoencefálica, e, uso da composição farmacêutica |
| WO2013021353A1 (en) | 2011-08-11 | 2013-02-14 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
| US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
| US10112987B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
| AU2015265872B2 (en) * | 2014-05-30 | 2020-04-09 | AbbVie Deutschland GmbH & Co. KG | Nanoencapsulation of antigen-binding molecules |
| CN106794150B (zh) * | 2014-05-30 | 2021-12-28 | 艾伯维德国有限责任两合公司 | 高药物负载的聚(2-氰基丙烯酸烷基酯)纳米胶囊 |
| EP3154524B1 (en) * | 2014-06-12 | 2021-12-15 | Adare Pharmaceuticals USA, Inc. | Extended-release drug delivery compositions |
| EP4299058A3 (en) | 2014-06-24 | 2024-03-27 | The Trustees of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| JP2021501753A (ja) * | 2017-11-03 | 2021-01-21 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿 |
| US12186436B2 (en) | 2018-07-19 | 2025-01-07 | The Trustees Of Princeton University | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| US20220031630A1 (en) * | 2018-09-13 | 2022-02-03 | The Brigham And Women's Hospital, Inc. | Nanoparticle formulations and methods of their use |
| US20200147032A1 (en) | 2018-11-14 | 2020-05-14 | Robert K. Prud'homme | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833666A (en) | 1986-12-24 | 1989-05-23 | U.S. Philips Corporation | Disc-record player suitable for scanning disc of different types |
| FR2649321A1 (fr) * | 1989-07-07 | 1991-01-11 | Inst Nat Sante Rech Med | Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques |
| FR2659554B1 (fr) * | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
| AU3462193A (en) * | 1993-02-15 | 1994-08-29 | Shield Research Limited | Polyalkylcyanoacrylate nanocapsules |
| EP0717617B1 (de) * | 1993-09-09 | 2000-10-25 | Schering Aktiengesellschaft | Wirkstoffe und gas enthaltende mikropartikel |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20030152636A1 (en) * | 2000-02-23 | 2003-08-14 | Nanopharm Ag | Method of treating cancer |
| US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
| EP2241309A3 (en) * | 2001-07-10 | 2012-12-26 | Corixa Corporation | Methods for encapsulation of proteins and adjuants in microspheres |
| TWI323265B (en) | 2002-08-06 | 2010-04-11 | Glaxo Group Ltd | Antibodies |
| US7993650B2 (en) | 2003-07-04 | 2011-08-09 | Affibody Ab | Polypeptides having binding affinity for HER2 |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
| PL1796650T3 (pl) | 2004-09-14 | 2009-06-30 | Nanodel Tech Gmbh | Nanocząstki zawierające dostarczające podłoże |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| SI1996621T1 (sl) | 2006-03-30 | 2010-04-30 | Glaxo Group Ltd | Protitelesa proti amiloidnemu peptidu beta |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| UA102993C2 (ru) | 2007-06-06 | 2013-09-10 | Домантис Лимитед | Анти-vegf единичный вариабельный домен иммуноглобулина |
-
2009
- 2009-05-05 KR KR1020107027449A patent/KR20110010760A/ko not_active Withdrawn
- 2009-05-05 CL CL2009001076A patent/CL2009001076A1/es unknown
- 2009-05-05 TW TW098114867A patent/TW201006495A/zh unknown
- 2009-05-05 PE PE2009000607A patent/PE20091829A1/es not_active Application Discontinuation
- 2009-05-05 AR ARP090101616A patent/AR071633A1/es not_active Application Discontinuation
- 2009-05-05 TW TW098114851A patent/TW201012488A/zh unknown
- 2009-05-05 CL CL2009001080A patent/CL2009001080A1/es unknown
- 2009-05-05 CL CL2009001077A patent/CL2009001077A1/es unknown
- 2009-05-05 US US12/991,556 patent/US20110064821A1/en not_active Abandoned
- 2009-05-05 AR ARP090101619A patent/AR072668A1/es not_active Application Discontinuation
- 2009-05-05 PE PE2009000606A patent/PE20091882A1/es not_active Application Discontinuation
- 2009-05-05 AR ARP090101617A patent/AR072359A1/es not_active Application Discontinuation
- 2009-05-05 KR KR1020107027240A patent/KR20110010758A/ko not_active Withdrawn
- 2009-05-05 KR KR1020107027425A patent/KR20110015604A/ko not_active Withdrawn
- 2009-05-05 UY UY0001031809A patent/UY31809A/es unknown
- 2009-05-05 UY UY0001031810A patent/UY31810A/es unknown
- 2009-05-05 AR ARP090101618A patent/AR071634A1/es not_active Application Discontinuation
- 2009-05-05 PE PE2009000608A patent/PE20091964A1/es not_active Application Discontinuation
- 2009-05-05 WO PCT/EP2009/055436 patent/WO2009135853A2/en not_active Ceased
- 2009-05-05 EP EP11192165A patent/EP2441447A1/en not_active Withdrawn
- 2009-05-05 UY UY0001031807A patent/UY31807A/es unknown
- 2009-05-05 TW TW098114853A patent/TW201012489A/zh unknown
- 2009-05-05 CL CL2009001081A patent/CL2009001081A1/es unknown
- 2009-05-05 TW TW098114865A patent/TW201012490A/zh unknown
- 2009-05-05 JP JP2011507897A patent/JP2011522792A/ja active Pending
- 2009-05-05 CA CA2721241A patent/CA2721241A1/en not_active Abandoned
- 2009-05-05 EP EP09742071A patent/EP2271323A2/en not_active Withdrawn
- 2009-05-05 PE PE2009000609A patent/PE20091965A1/es not_active Application Discontinuation
- 2009-05-05 UY UY0001031808A patent/UY31808A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522792A5 (enExample) | ||
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| Yuan et al. | Ocular drug delivery nanowafer with enhanced therapeutic efficacy | |
| Yavuz et al. | In vitro/in vivo evaluation of dexamethasone—PAMAM dendrimer complexes for retinal drug delivery | |
| Sun et al. | Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma | |
| Li et al. | Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration | |
| Schnichels et al. | Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment | |
| CA2947067C (en) | Compounds for treating ophthalmic diseases and disorders | |
| JP2017537985A5 (enExample) | ||
| Xue et al. | Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor | |
| Feng et al. | Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection | |
| JP2017061467A5 (enExample) | ||
| AU2019202037A1 (en) | Sunitinib formulations and methods for use thereof in treatment of ocular disorders | |
| WO2013090804A2 (en) | Nanoparticles with enhanced mucosal penetration or decreased inflammation | |
| Ghafoorianfar et al. | Efficiency of nanoparticles for treatment of ocular infections: Systematic literature review | |
| JP2016521712A5 (enExample) | ||
| JP2014533698A5 (enExample) | ||
| WO2004050060A1 (ja) | 結膜下デポによるドラッグデリバリーシステム | |
| Pita-Thomas et al. | Nanotechnology and glaucoma: little particles for a big disease | |
| KR20130007531A (ko) | 유리체강내 주입을 위한 방법, 장치, 및 조성물 | |
| JP2017527600A5 (enExample) | ||
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP2015520241A5 (enExample) | ||
| Martinez-Sancho et al. | Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release | |
| Sharma et al. | A Mini-review on New Developments in nanocarriers and polymers for ophthalmic drug delivery strategies |